IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference

Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) will participate in the 2026 Jefferies Global Healthcare Conference in early June 2026. The company’s President and CEO, Yujiro S. Hata, will join a fireside chat and an AI panel, both accessible via webcast on IDEAYA’s investor website.

News Market Reaction – IDYA

+0.86%

+0.86% Session close to close

In the May 26 session, IDYA gained 0.86%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights IDEAYA’s participation at the 2026 Jefferies Global Healthcare Conferen...

Analysis

This announcement highlights IDEAYA’s participation at the 2026 Jefferies Global Healthcare Conference, featuring a fireside chat and an AI-focused panel with the CEO on June 3 and June 4. It fits a broader pattern of active scientific and investor engagement around darovasertib’s registrational program and a deep synthetic lethality/ADC pipeline. Against a backdrop of prior positive Phase 2/3 data and substantial cash of $972.9M, investors may watch for any incremental clinical, regulatory, or business commentary emerging from these appearances.

Key Figures

ATM capacity: $156.6 million ATM shelf size: $350,000,000 ATM used: $193,447,003.19 +5 more

8 metrics

ATM capacity $156.6 million Potential common stock sales under Open Market Sales Agreement (8-K, 2026-05-05)

ATM shelf size $350,000,000 Aggregate ATM program capacity via Jefferies (424B5, 2026-05-05)

ATM used $193,447,003.19 Common stock already sold under ATM (424B5, 2026-05-05)

ATM remaining $156,552,996.81 Remaining capacity under ATM program (424B5, 2026-05-05)

Collaboration revenue $6.6 million Q1 2026 collaboration revenue (10-Q, 2026-05-05)

R&D expense $95.7 million Q1 2026 research and development (10-Q, 2026-05-05)

Net loss $98.5 million Q1 2026 net loss (10-Q/8-K, 2026-05-05)

Cash and securities $972.9 million Liquidity as of March 31, 2026 (10-Q/8-K)

Historical Context

5 past events · Latest: May 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 05	Earnings and update	Positive	-0.3%	Q1 2026 results, pivotal trial win and strong cash runway disclosure.
May 01	Inducement grants	Neutral	-3.1%	Stock option grants to new hires under Nasdaq inducement rules.
Apr 30	RTOR NDA plan	Positive	+3.7%	Plan to initiate FDA RTOR NDA submission after positive OptimUM-02 topline.
Apr 21	ASCO data preview	Positive	-5.3%	Announcement of late‑breaking ASCO oral presentation with full trial data.
Apr 13	Topline trial results	Positive	+7.6%	Positive Phase 2/3 OptimUM-02 data in first‑line metastatic uveal melanoma.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive clinical and liquidity updates often saw mixed reactions, with several divergences between strong news and short-term price moves.

Recent Company History

Over recent months, IDEAYA highlighted multiple milestones around darovasertib and corporate development. Positive Phase 2/3 OptimUM-02 topline data on Apr 13, 2026 and follow‑on ASCO presentation plans on Apr 21, 2026 framed a clear registrational path. Subsequent RTOR NDA plans on Apr 30, 2026 and Q1 2026 earnings on May 5, 2026 emphasized strong liquidity of $972.9M. Against that backdrop, this Jefferies conference participation fits a pattern of active visibility and ongoing investor outreach rather than a new clinical or financial inflection point.

Key Terms

precision medicine, oncology, antibody-drug conjugates, synthetic lethality, +4 more

8 terms

precision medicine medical

"IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed"

Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.

oncology medical

"IDEAYA is a precision medicine oncology company committed to the discovery, development"

Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets—think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.

antibody-drug conjugates medical

"product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly"

A class of targeted cancer medicines that combine a lab-made antibody (which finds and sticks to specific markers on tumor cells) with a powerful cell-killing drug linked together so the toxic payload is delivered directly to the tumor. Think of it like a guided missile that reduces collateral damage compared with traditional chemotherapy; for investors, success or failure of these drugs drives clinical, regulatory and commercial value and can sharply affect a biotech company’s prospects and stock price.

synthetic lethality medical

"We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug"

Synthetic lethality occurs when two separate weaknesses in a cell—each harmless alone—combine to cause the cell to die; targeting the partner weakness lets a drug kill diseased cells while sparing healthy ones. Think of it like removing the second support of a wobbly chair: a targeted nudge collapses only the defective ones. For investors, therapies based on this idea can offer more precise drugs, clearer patient selection tests, and potentially faster, less risky development paths.

biomarkers medical

"capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class"

Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.

at-the-market offering financial

"filed a prospectus supplement for an at-the-market offering under a shelf registration that permits up"

An at-the-market offering is a method companies use to sell new shares of stock directly into the open market over time, rather than all at once. This allows them to raise money gradually, similar to selling small pieces of a product instead of a large batch. For investors, it means the company can access funding more flexibly, but it may also increase the supply of shares and influence the stock’s price.

automatic shelf registration statement regulatory

"filed an automatic shelf registration statement to offer Common Stock, Preferred Stock, Debt Securities"

An automatic shelf registration statement is a pre-approved filing that companies submit to securities regulators, allowing them to sell new shares or bonds quickly and efficiently when needed. It acts like a standing permit, enabling the company to raise money without going through a lengthy approval process each time, which can be helpful for responding promptly to market opportunities or needs. For investors, it provides transparency about the company's ability to raise funds and signals planning flexibility.

warrants financial

"automatic shelf registration statement to offer Common Stock, Preferred Stock, Debt Securities, Warrants and Units"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., May 26, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the following events at the 2026 Jefferies Global Healthcare Conference.

2026 Jefferies Global Healthcare Conference
Wednesday, June 3rd, 2026 at 7:35 AM ET

• Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Maury Raycroft, Ph.D. Equity Research Analyst, Biotechnology

AI Panel at the 2026 Jefferies Global Healthcare Conference
Thursday, June 4th, 2026 from 8:45 AM ET

• Panel discussion featuring Yujiro S. Hata, President and Chief Executive Officer, moderated by Akash Tewari, Global Head of Biopharmaceutical Research

A live audio webcast of the conference events, as permitted by the conference host, will be available under the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of the webcasts will be accessible for 30 days following the live event.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer.  Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease.  We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications.  Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 17, 2026.

Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski
Chief Financial Officer
investor@ideayabio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-participation-at-the-2026-jefferies-global-healthcare-conference-302781313.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

When will IDEAYA Biosciences (NASDAQ: IDYA) present at the 2026 Jefferies Global Healthcare Conference?

IDEAYA Biosciences will present on June 3, 2026, at 7:35 AM ET in a fireside chat. According to IDEAYA, CEO Yujiro S. Hata will also join an AI panel on June 4, 2026, at 8:45 AM ET.

What sessions will IDEAYA Biosciences (IDYA) join at the 2026 Jefferies Global Healthcare Conference?

IDEAYA Biosciences will join a fireside chat and an AI panel at the 2026 Jefferies Global Healthcare Conference. According to IDEAYA, both sessions will feature President and CEO Yujiro S. Hata discussing the company and broader biotechnology and AI themes.

How can investors listen to IDEAYA Biosciences’ 2026 Jefferies Global Healthcare Conference webcast?

Investors can access a live audio webcast via the IDEAYA “Investors/Events” website section or the conference host. According to IDEAYA, a replay of the webcasts will also be available for 30 days following the live events for on-demand listening.

Who will represent IDEAYA Biosciences (IDYA) at the 2026 Jefferies Global Healthcare Conference?

IDEAYA will be represented by Yujiro S. Hata, its President and Chief Executive Officer. According to IDEAYA, he will participate in both a fireside chat hosted by an equity research analyst and an AI panel moderated by a biopharmaceutical research leader.

What does IDEAYA Biosciences (NASDAQ: IDYA) focus on in oncology?

IDEAYA Biosciences focuses on precision medicine oncology, developing targeted therapies for cancer. According to IDEAYA, its pipeline includes synthetic lethality and antibody-drug conjugate (ADC) programs for molecularly defined solid tumors, supported by internal biomarker, structural biology, and small-molecule discovery capabilities.

What is the AI panel involving IDEAYA Biosciences at the 2026 Jefferies conference?

The AI panel is a discussion at the 2026 Jefferies Global Healthcare Conference featuring IDEAYA’s CEO, Yujiro S. Hata. According to IDEAYA, the session will be moderated by Akash Tewari, Global Head of Biopharmaceutical Research, and will explore biotechnology and AI-related topics.